Citigroup: Novo Nordisk has obtained a respite.

Citigroup analyst wrote that Novo Nordisk has been given a respite, as Hims & Hers announced that they will stop offering a generic version of the Danish pharmaceutical company's weight loss drug Wegovy. Hims & Hers only launched the drug on Thursday. Novo Nordisk has stated that they will take legal and regulatory action, with the General Counsel of the US Department of Health and Human Services transferring the case to the Justice Department for investigation, and the US Food and Drug Administration stating that they will take measures to restrict the unauthorized preparation of drugs. Citigroup stated that this news allows Novo Nordisk to temporarily not compete with the prepared Wegovy, and may help limit the impact of the injectable prepared Wegovy in the future. However, the firm still believes that Novo Nordisk will face multiple sales and pricing disadvantages in 2026 and beyond.